Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

21st November 2019 Uncategorised 0

Amgen has its $13.4 billion purchase of Celgene’s psoriasis blockbuster Otezla in the bag, but will the buy pay off to the extent the company is predicting? Analysts are cautiously optimistic.

More: Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla
Source: fierce